Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relevance of the c.557A>G variant for the implementation of DPYD pharmacogenetics in populations with Afro-Latin American ancestry.

Drug metabolism and personalized therapy - 1 Mar 2026

González de la Cruz Carla, Rodrigues-Soares Fernanda, Guevara Mariela, Rodríguez Ernesto, Manóchio Caíque, Peñas-Lledó Eva, Dorado Pedro, LLerena Adrián

Abstract excerpt

Fluoropyrimidines are chemotherapy treatments widely used in chemotherapeutic regimens for different types of cancer. Adverse effects produced by dihydropyrimidine dehydrogenase (DPD) enzyme deficiency due to single nucleotide variants (SNVs) in the limiting enzyme of fluoropyrimidine catabolism occur with a high frequency in the world population; however, clinical recommendation guidelines focus mainly on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Black or African American
Share to Dihydrouracil Dehydrogenase (NADP)

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DPYD gene

Share to Latin America

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 41247728
DOI: 10.1515/dmpt-2025-0070

Genes

DPYD

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relevance of the c.557A>G variant for the implementation of DPYD pharmacogenetics in populations with Afro-Latin American ancestry.PMID 41247728Read ↗

Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the LiteratureSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.Semantic proximity Read ↗

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.Semantic proximity Read ↗

Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and OpportunitiesSemantic proximity Read ↗

Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.Semantic proximity Read ↗

DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?Semantic proximity Read ↗

Genetic Variations of the DPYD Gene and Its Relationship with Ancestry Proportions in Different Ecuadorian Trihybrid PopulationsSemantic proximity Read ↗

Frequency of DPYD gene variants and phenotype inference in a Southern Brazilian population.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.Semantic proximity Read ↗

[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].Semantic proximity Read ↗

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in GreeceSemantic proximity Read ↗

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.